Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

7.690 -0.250 (-3.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
Via ACCESS Newswire
News headline image
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
From NeoGenomics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
Via ACCESS Newswire
News headline image
A Look at NeoGenomics's Upcoming Earnings Report ↗
 
Via Benzinga
News headline image
3 Cash-Burning Stocks Facing Headwinds
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to... 
Via StockStory
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
3 Unprofitable Stocks in Hot Water
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
News headline image
3 Volatile Stocks in Hot Water
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
News headline image
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
From NeoGenomics, Inc.
Via Business Wire
News headline image
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
From NeoGenomics, Inc.
Via Business Wire
News headline image
Envista, NeoGenomics, Acadia Healthcare, Astrana Health, and Hims & Hers Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could... 
Via StockStory
Topics Bonds Stocks
News headline image
NeoGenomics to Participate in Upcoming June Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
News headline image
3 Healthcare Stocks with Mounting Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
News headline image
3 Russell 2000 Stocks in the Doghouse
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
News headline image
NEO Q1 Earnings Call: Sales Growth, Pharma Headwinds, and Pathline Integration Shape Outlook
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the... 
Via StockStory
News headline image
Earnings Scheduled For May 9, 2025 ↗
 
Via Benzinga
News headline image
Assessing NeoGenomics: Insights From 9 Financial Analysts ↗
 
Via Benzinga
News headline image
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays
These three stocks may fly under the radar, but their recent price increases could appeal to investors seeking a momentum play. 
Via MarketBeat
Topics World Trade
News headline image
3 Small-Cap Stocks Walking a Fine Line
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
NeoGenomics Pays Off 1.25% Convertible Senior Notes
From NeoGenomics, Inc.
Via Business Wire
News headline image
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Tuesday's session: top gainers and losers ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Why NeoGenomics (NEO) Stock Is Nosediving
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 34.8% in the afternoon session after the company reported disappointing first-quarter 2025 earnings as sales fell below... 
Via StockStory
Topics Artificial Intelligence
News headline image
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings ↗
 
Via Benzinga
News headline image
NeoGenomics (NASDAQ:NEO) Misses Q1 Sales Targets, Stock Drops
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.